|
Video: What is a Stock Split?
|
|
YY-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the FDA, in combination with granulocyte-macrophage Colony-Stimulating factor for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Co.'s product candidate, 131I-omburtamab, is in development for pediatric central nervous system/leptomeningeal metastases from neuroblastoma - a rare and life-threatening pediatric cancer According to our YMAB split history records, Y-mAbs Therapeutics has had 0 splits. | |
|
Y-mAbs Therapeutics (YMAB) has 0 splits in our YMAB split history database.
Looking at the YMAB split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Y-mAbs Therapeutics shares, starting with a $10,000 purchase of YMAB, presented on a split-history-adjusted basis factoring in the complete YMAB split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/24/2018 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$26.97 |
|
End price/share: |
$16.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-38.82% |
|
Average Annual Total Return: |
-8.53% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,118.73 |
|
Years: |
5.51 |
|
|
|
|
|